Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
Wang, X.; Sacramento, C. Q.; Jockusch, S.; Chaves, O. A.; Tao, C.; Fintelman-Rodrigues, N.; Chien, M.; Temerozo, J. R.; Li, X.; Kumar, S.; Xie, W.; Patel, D. J.; Meyer, C.; Garzia, A.; Tuschl, T.; Bozza, P. T.; Russo, J. J.; Souza, T. M. L.; Ju, J.
Show abstract
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of both the viral RNA-dependent RNA polymerase and the exonuclease could overcome this deficiency. Here we report the identification of hepatitis C virus NS5A inhibitors Pibrentasvir and Ombitasvir as SARS-CoV-2 exonuclease inhibitors. In the presence of Pibrentasvir, RNAs terminated with the active forms of the prodrugs Sofosbuvir, Remdesivir, Favipiravir, Molnupiravir and AT-527 were largely protected from excision by the exonuclease, while in the absence of Pibrentasvir, there was rapid excision. Due to its unique structure, Tenofovir-terminated RNA was highly resistant to exonuclease excision even in the absence of Pibrentasvir. Viral cell culture studies also demonstrate significant synergy using this combination strategy. This study supports the use of combination drugs that inhibit both the SARS-CoV-2 polymerase and exonuclease for effective COVID-19 treatment.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 94%
- Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture 94%
- Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease 93%
Similar papers in this journal
- Mechanistic insights into the activity of SARS-CoV-2 RNA polymerase inhibitors using single-molecule FRET 95%
- Allosteric regulation and crystallographic fragment screening of SARS-CoV-2 NSP15 endoribonuclease 94%
- The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5' cap modulates protein expression in living cells 94%
Similar papers in this journal
- Small Molecule Targeting IRES Domain Inhibits Enterovirus 71 Replication via an Allosteric Mechanism that Stabilizes a Ternary Complex 96%
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
- Structural analysis of the SARS-CoV-2 methyltransferase complex involved in coronaviral RNA cap creation 95%
Similar papers in this journal
- A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19 95%
- Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo 94%
- A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors 94%
Similar papers in this journal
- The Effect Of Famotidine On SARS-CoV-2 Proteases And Virus Replication 94%
- Tryptophan-like side chain holding aptamers inhibit respiratory syncytial virus infection of lung epithelial cells 94%
- Antiviral activity of lambda-carrageenan against influenza viruses in mice and severe acute respiratory syndrome coronavirus 2 in vitro 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.